Na Shen

300 Guangzhou Road
Nanjing, 210029, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Drug-Induced Cuproptosis Defines the Therapeutic Window of Celecoxib in Intervertebral Disc Degeneration via the HSP90-RBX1 Axis.

Drug-Induced Cuproptosis Defines the Therapeutic Window of Celecoxib in Intervertebral Disc Degeneration via the HSP90-RBX1 Axis.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 19, 2026

Prognostic value of the neutrophil-to-lymphocyte ratio in POEMS syndrome.

Prognostic value of the neutrophil-to-lymphocyte ratio in POEMS syndrome.

Journal: Clinical and experimental medicine
Published: January 22, 2026

Decreased Expression of FAT4 Promotes Multiple Myeloma Proliferation and Migration by Targeting the Hippo/YAP Pathway.

Decreased Expression of FAT4 Promotes Multiple Myeloma Proliferation and Migration by Targeting the Hippo/YAP Pathway.

Journal: Cancer science
Published: October 11, 2025

Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy.

Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy.

Journal: Cell death & disease
Published: May 17, 2025

HSPA9 contributes to tumor progression and ferroptosis resistance by enhancing USP14-driven SLC7A11 deubiquitination in multiple myeloma.

HSPA9 contributes to tumor progression and ferroptosis resistance by enhancing USP14-driven SLC7A11 deubiquitination in multiple myeloma.

Journal: Cell reports
Published: January 10, 2025

Exosome-transmitted HSPA9 facilitates bortezomib resistance by targeting TRIP13/USP1 signaling in multiple myeloma.

Exosome-transmitted HSPA9 facilitates bortezomib resistance by targeting TRIP13/USP1 signaling in multiple myeloma.

Journal: Cell communication and signaling : CCS
Published: December 29, 2024

Clinical characteristics and prognosis of newly diagnosed multiple myeloma patients with FGFR3 gene mutations

Clinical characteristics and prognosis of newly diagnosed multiple myeloma patients with FGFR3 gene mutations

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 19, 2024

Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease.

Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease.

Journal: Annals of medicine
Published: December 12, 2023

AMPKα1-mediated ZDHHC8 phosphorylation promotes the palmitoylation of SLC7A11 to facilitate ferroptosis resistance in glioblastoma.

AMPKα1-mediated ZDHHC8 phosphorylation promotes the palmitoylation of SLC7A11 to facilitate ferroptosis resistance in glioblastoma.

Journal: Cancer letters
Published: October 10, 2023

ZDHHC5-mediated S-palmitoylation of FAK promotes its membrane localization and epithelial-mesenchymal transition in glioma.

ZDHHC5-mediated S-palmitoylation of FAK promotes its membrane localization and epithelial-mesenchymal transition in glioma.

Journal: Cell communication and signaling : CCS
Published: August 05, 2023

The E3 ligase TRIM26 suppresses ferroptosis through catalyzing K63-linked ubiquitination of GPX4 in glioma.

The E3 ligase TRIM26 suppresses ferroptosis through catalyzing K63-linked ubiquitination of GPX4 in glioma.

Journal: Cell death & disease
Published: July 06, 2023

TRIM3 facilitates ferroptosis in non-small cell lung cancer through promoting SLC7A11/xCT K11-linked ubiquitination and degradation.

TRIM3 facilitates ferroptosis in non-small cell lung cancer through promoting SLC7A11/xCT K11-linked ubiquitination and degradation.

Journal: Cell death and differentiation
Published: June 01, 2023
Showing 1-12 of 14

Last Updated: 09/26/2026